Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb.

摘要: Medically important cases of snakebite in Europe are predominately caused by European vipers the genus Vipera. The mainstay therapy is polyclonal antibody therapy, referred to as antivenom. Here we investigate capability monospecific V. berus antivenom, ViperaTAb®, cross-react with, and neutralise lethality induced by, a variety vipers. Using ELISA immunoblotting, find that ViperaTAb® antibodies recognise bind majority toxic components found venoms Vipera species tested at comparably high levels those observed with berus. vivo pre-clinical efficacy studies, demonstrate effectively neutralises berus, aspis, ammodytes latastei much higher than outlined regulatory pharmacopoeial guidelines. Notably, venom neutralisation was be superior (V. aspis latastei), or equally effective ammodytes), “Zagreb antivenom”, which has long been successfully used for treating snake envenomings. This study suggests may valuable therapeutic product throughout continent.